Cardiol Therapeutics (CRDL) Total Liabilities (2020 - 2026)

Cardiol Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 4.2% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 4.2% YoY), and the FY2025 full-year result was $4.1 million, down 19.38% from the prior year.
• Total Liabilities for Q1 2026 stood at $5.3 million, up from $4.1 million in the prior quarter.
• The five-year high for Total Liabilities was $9.0 million in Q2 2022, with the low at $2.5 million in Q3 2025.
• Historically, Total Liabilities has averaged $6.2 million across 5 years, with a median of $6.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 265.3% — and 2025, when it slumped 52.64%.
• Cardiol Therapeutics' Total Liabilities stood at $7.2 million in 2022, then retreated by 14.22% to $6.2 million in 2023, then declined by 17.75% to $5.1 million in 2024, then slipped by 19.38% to $4.1 million in 2025, then climbed by 27.56% to $5.3 million in 2026.
• The last three Total Liabilities figures came in at $5.3 million (Q1 2026), $4.1 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.